A Phase 2 Study of Olaparib Monotherapy in Metastatic Breast Cancer Patients With Germline or Somatic Mutations in DNA Repair Genes (Olaparib Expanded)
Phase of Trial: Phase II
Latest Information Update: 28 Aug 2019
Price : $35 *
At a glance
- Drugs Olaparib (Primary)
- Indications Advanced breast cancer; Male breast cancer
- Focus Therapeutic Use
- 27 Mar 2018 Status changed from not yet recruiting to recruiting.
- 17 Dec 2017 Planned primary completion date changed from 31 Dec 2019 to 30 Jan 2020.
- 17 Dec 2017 Planned initiation date changed from 30 Nov 2017 to 30 Jan 2018.